Multicenter Clinical Study on the Optimal Treatment Protocol and Outcome of Cough Variant Asthma With Chinese and Western Medicine
NCT ID: NCT05459805
Last Updated: 2023-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
164 participants
INTERVENTIONAL
2022-03-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Clinical Study on the Clinical Efficacy and Prognostic Outcome of ICS/LABA Combined With Liqin Zhike Formula in the Treatment of Cough Variant Asthma
NCT07272278
Chinese Herbal Medicine Formula Combined With Inhaled Corticosteroids for the Treatment of Mild to Persistent Asthma in Children
NCT05066841
A Clinical Study on the Prevention of Mild to Moderate Intermittent Asthma With Chinese Medicine Weiyang Yuping Fang
NCT04522726
Clinical Study on Treatment of Chronic Persistent Bronchial Asthma
NCT03228134
Clinical Characteristics, Treatment and Prognosis of Chest Tightness Variant Asthma
NCT03237221
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1
those receive ICS/LABA plus traditional Chinese medicine
traditional chinese medicine Xuanfei-Zhike formula
200ml, bid, for 8 weeks
inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA)
one suction, q12h, for 8 weeks
group 2
those receive ICS/LABA alone
inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA)
one suction, q12h, for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
traditional chinese medicine Xuanfei-Zhike formula
200ml, bid, for 8 weeks
inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA)
one suction, q12h, for 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. 18 years≤age≤65 years;
3. agree to participant in this trial.
Exclusion Criteria
2. history of mental illness;
3. comorbidity of heart and cardiovascular, liver, kidney and hematopoietic function and other severe diseases;
4. participants of other clinical trials who may make a difference in our trial;
5. treatment with other Chinese herb.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xin Hua Hospital of Zhejiang Province
OTHER
Hangzhou Hospital of Traditional Chinese Medicine
OTHER
Affiliated Wenling Hospital of Wenzhou Medical University
OTHER
The First Affiliated Hospital of Zhejiang Chinese Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Junchao Yang
Role: STUDY_CHAIR
The First Affiliated Hospital of Zhejiang Chinese Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hangzhou Hospital of Traditional Chinese Medicine
Hangzhou, , China
The First Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, , China
Xin Hua Hospital of Zhejiang Province
Hangzhou, , China
The First People's Hospital of Wenling
Taizhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChiCTR2100048636
Identifier Type: REGISTRY
Identifier Source: secondary_id
2022ZZ011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.